Investigating how a protein involved in DNA damage response helps prevent tumors
Official title: The nuclear Ferredoxin reductase and its role in tumor suppression
Funded at University of California at Davis · NIH-11065500 · Data updated 2026-11-12
This study is looking at a protein called FDXR that helps our cells deal with DNA damage and may help stop tumors from growing, and it's for anyone interested in how understanding this protein could lead to new ways to treat cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $479,793 |
| NIH project number | 5R01CA283368-02 |
| Project ID | NIH-11065500 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with cancers, particularly those related to DNA damage and tumor suppression mechanisms.
✕Less likely to help
Patients with tumors that do not involve the mechanisms of DNA damage response or those who are not diagnosed with cancer may not benefit from this research.
What this research studies
This research focuses on ferredoxin reductase (FDXR), a protein that plays a crucial role in the body's response to DNA damage and may help suppress tumor growth. The study aims to understand how FDXR is regulated within cells and how it functions in the nucleus to influence cell survival and growth, particularly in the context of cancer. By examining the interactions of FDXR with other important proteins like p53, the research seeks to uncover new insights into tumor suppression mechanisms. Patients may benefit from this research as it could lead to novel therapeutic strategies for cancer treatment.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance the body's ability to suppress tumor growth.
How similar studies have gone: Other research has shown promising results in understanding the role of proteins like FDXR in cancer biology, suggesting that this approach has potential for success.
Where this research is happening
-
University of California at Davis
Davis, United States Active
Researchers
- Principal investigator: Chen, Xinbin — University of California at Davis
- Study coordinator: Chen, Xinbin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.